- Home
- MNSB vs MNPR Comparison
MNSB vs MNPR Comparison
Compare MNSB & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNSB
- MNPR
- Stock Information
- Founded
- MNSB 2003
- MNPR 2014
- Country
- MNSB United States
- MNPR United States
- Employees
- MNSB N/A
- MNPR N/A
- Industry
- MNSB Major Banks
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- MNSB Finance
- MNPR Health Care
- Exchange
- MNSB Nasdaq
- MNPR Nasdaq
- Market Cap
- MNSB 133.8M
- MNPR 113.5M
- IPO Year
- MNSB N/A
- MNPR 2019
- Fundamental
- Price
- MNSB $18.80
- MNPR $25.82
- Analyst Decision
- MNSB
- MNPR Strong Buy
- Analyst Count
- MNSB 0
- MNPR 3
- Target Price
- MNSB N/A
- MNPR $27.33
- AVG Volume (30 Days)
- MNSB 12.7K
- MNPR 101.2K
- Earning Date
- MNSB 01-21-2025
- MNPR 11-08-2024
- Dividend Yield
- MNSB 2.13%
- MNPR N/A
- EPS Growth
- MNSB N/A
- MNPR N/A
- EPS
- MNSB 1.21
- MNPR N/A
- Revenue
- MNSB $62,730,000.00
- MNPR N/A
- Revenue This Year
- MNSB N/A
- MNPR N/A
- Revenue Next Year
- MNSB $8.55
- MNPR N/A
- P/E Ratio
- MNSB $15.58
- MNPR N/A
- Revenue Growth
- MNSB N/A
- MNPR N/A
- 52 Week Low
- MNSB $14.97
- MNPR $1.55
- 52 Week High
- MNSB $25.02
- MNPR $38.50
- Technical
- Relative Strength Index (RSI)
- MNSB 49.16
- MNPR 57.88
- Support Level
- MNSB $17.99
- MNPR $22.61
- Resistance Level
- MNSB $20.88
- MNPR $32.20
- Average True Range (ATR)
- MNSB 0.65
- MNPR 3.36
- MACD
- MNSB -0.13
- MNPR -0.03
- Stochastic Oscillator
- MNSB 28.03
- MNPR 47.01
About MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.